JP2004507559A - ＥｒｂＢ４アンタゴニスト - Google Patents

ＥｒｂＢ４アンタゴニスト Download PDF

Info

Publication number
JP2004507559A
JP2004507559A JP2002523958A JP2002523958A JP2004507559A JP 2004507559 A JP2004507559 A JP 2004507559A JP 2002523958 A JP2002523958 A JP 2002523958A JP 2002523958 A JP2002523958 A JP 2002523958A JP 2004507559 A JP2004507559 A JP 2004507559A
Authority
JP
Japan
Prior art keywords
antibody
erbb4
number pta
accession number
atcc accession
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002523958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004507559A5 (enExample
Inventor
ゲリットセン，　マリー　イー．
スリウコウスキ，　マーク　エックス．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2004507559A publication Critical patent/JP2004507559A/ja
Publication of JP2004507559A5 publication Critical patent/JP2004507559A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2002523958A 2000-09-01 2001-08-29 ＥｒｂＢ４アンタゴニスト Pending JP2004507559A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22967900P 2000-09-01 2000-09-01
US26551601P 2001-01-31 2001-01-31
US09/940,101 US20020119148A1 (en) 2000-09-01 2001-08-27 ErbB4 antagonists
PCT/US2001/026984 WO2002018444A2 (en) 2000-09-01 2001-08-29 Erbb4 antagonists

Publications (2)

Publication Number Publication Date
JP2004507559A true JP2004507559A (ja) 2004-03-11
JP2004507559A5 JP2004507559A5 (enExample) 2008-10-09

Family

ID=27397993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002523958A Pending JP2004507559A (ja) 2000-09-01 2001-08-29 ＥｒｂＢ４アンタゴニスト

Country Status (11)

Country Link
US (6) US20020119148A1 (enExample)
EP (1) EP1351744B1 (enExample)
JP (1) JP2004507559A (enExample)
AT (1) ATE374642T1 (enExample)
AU (2) AU2001286918B2 (enExample)
CA (1) CA2420062C (enExample)
DE (1) DE60130797T2 (enExample)
DK (1) DK1351744T3 (enExample)
ES (1) ES2295202T3 (enExample)
IL (2) IL154495A0 (enExample)
WO (1) WO2002018444A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
WO2002098445A1 (fr) * 2001-05-30 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preparation de proteines
AU2003237367A1 (en) * 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
DK2263691T3 (da) 2002-07-15 2012-10-22 Hoffmann La Roche Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4)
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
JP4527388B2 (ja) * 2003-12-11 2010-08-18 東洋鋼鈑株式会社 ポリペプチドとレセプターとの相互作用を検出する方法、該検出する方法を用いてリガンドまたはリガンド変異体をスクリーニングする方法および該検出する方法を用いる診断方法
CN114053429A (zh) 2004-06-01 2022-02-18 健泰科生物技术公司 抗体-药物偶联物和方法
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1856158A4 (en) * 2005-03-07 2010-07-28 Targeted Molecular Diagnostics TYROSINE KINASE INHIBITOR COMPOSITIONS AND METHODS OF MAKING SAME AND USE THEREOF IN TREATING DISEASE
JP5564266B2 (ja) * 2007-02-16 2014-07-30 メリマック ファーマシューティカルズ インコーポレーティッド Ｅｒｂｂ３に対する抗体およびその使用
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
US8623592B2 (en) * 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
SI2365987T1 (sl) 2008-11-25 2015-03-31 Genentech, Inc. Izoformno specifična protitelesa proti HER4
JP5624114B2 (ja) * 2009-03-20 2014-11-12 ジェネンテック， インコーポレイテッド 抗ｈｅｒ抗体
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
CA2789154C (en) 2010-02-08 2024-06-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
WO2011107100A1 (en) 2010-03-03 2011-09-09 Aarhus Universitet Methods and compositions for regulation of herv4
EP2544680B1 (en) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative breast cancer
WO2012099566A1 (en) 2010-11-17 2012-07-26 Sea Lane Biotechnologies, Llc Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
RS66089B1 (sr) 2011-08-05 2024-11-29 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
EP2748197A2 (en) 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
AR093778A1 (es) * 2012-11-08 2015-06-24 Hoffmann La Roche PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4
KR20150064205A (ko) 2012-11-08 2015-06-10 에프. 호프만-라 로슈 아게 Her3의 베타-헤어핀에 결합하는 her3 항원 결합 단백질
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
FR3020063A1 (fr) * 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
EP3143048B1 (en) 2014-05-14 2019-08-28 F. Hoffmann-La Roche AG Anti-her3 antibodies binding to the beta-hairpin of her3
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
US20230040928A1 (en) * 2019-12-09 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002540A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
WO1998002541A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Gamma-heregulin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2037440A1 (en) 1990-03-02 1991-09-03 Gregory D. Plowman Her3: a novel egf receptor homolog
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
AU675916B2 (en) * 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
SK281724B6 (sk) * 1994-11-14 2001-07-10 Warner-Lambert Company 6-arylpyrido[2,3-d]pyrimidíny, ich použitie a farmaceutické prostriedky na ich báze
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
ES2335365T3 (es) * 1996-11-27 2010-03-25 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteina a.
US6121415A (en) 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
US6994856B1 (en) * 1997-07-24 2006-02-07 Genentech, Inc. ErbB4 receptor-specific neuregulin related ligands and uses therefor
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
HUP0104211A3 (en) 1998-11-19 2003-01-28 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases and pharmaceutical composition containing it
ES2300340T3 (es) * 2000-06-06 2008-06-16 Bristol-Myers Squibb Company Acidos nucleicos y polipeptidos relacionados con b7 y sus usos para inmunomodulacion.
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002540A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
WO1998002541A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Gamma-heregulin

Also Published As

Publication number Publication date
US7704498B2 (en) 2010-04-27
HK1059404A1 (en) 2004-07-02
DK1351744T3 (da) 2008-02-11
EP1351744B1 (en) 2007-10-03
US20060093603A1 (en) 2006-05-04
AU2001286918B2 (en) 2006-12-21
CA2420062A1 (en) 2002-03-07
US20040052786A1 (en) 2004-03-18
ES2295202T3 (es) 2008-04-16
US20100190964A1 (en) 2010-07-29
US7332579B2 (en) 2008-02-19
EP1351744A2 (en) 2003-10-15
US20090068205A1 (en) 2009-03-12
US20020119148A1 (en) 2002-08-29
WO2002018444A2 (en) 2002-03-07
US20070092513A1 (en) 2007-04-26
IL154495A (en) 2009-12-24
IL154495A0 (en) 2003-09-17
WO2002018444A3 (en) 2003-07-31
DE60130797D1 (de) 2007-11-15
ATE374642T1 (de) 2007-10-15
AU8691801A (en) 2002-03-13
CA2420062C (en) 2014-04-01
DE60130797T2 (de) 2008-08-07

Similar Documents

Publication Publication Date Title
US7704498B2 (en) ErbB4 antagonists
AU2001286918A1 (en) ErbB4 antagonists
DE69936382T2 (de) Therapeutische verwendungen von il-17 homologe polypeptide
AU705107B2 (en) HTK ligand
US20110287024A1 (en) Vascular endothelial cell growth factor antagonists
EP1328547B1 (en) Identification and modification of immunodominant epitopes in polypeptides
JP2015108015A (ja) Ｉｌ−１７ａ／ｆヘテロ二量体ポリペプチドおよびその治療上の使用
CA2241564A1 (en) Wsx receptor and ligands
PL202396B1 (pl) Neutralizujące przeciwciało monoklonalne szczurze, kwas nukleinowy kodujący to przeciwciało, kompozycja farmaceutyczna i zastosowanie przeciwciała lub fragmentu neutralizującego tego przeciwciała do wytwarzania leku do leczenia stanów w których uczestniczy IL-18
KR20050049470A (ko) 항 수초 관련 당단백질 항체
US20020032313A1 (en) Vascular endothelial cell growth factor antagonists
US20030023046A1 (en) Vascular endothelial cell growth factor antagonists
JP2005508605A (ja) チンパンジーエリスロポイエチン（ｃｈｅｐｏ）−免疫接着因子
JP3660880B2 (ja) 新規なチンパンジーエリスロポエチン（ｃｈｅｐｏ）ポリペプチドおよびこれをコードする核酸
JP2009219492A (ja) Ｇｄｎｆｒと配列類似性を有する新規ポリペプチド及びこれをコードする核酸
US7259245B2 (en) Anti-fused antibodies
HK1059404B (en) Use of specific erbb4 antagonists for treating stenosis
JP4166254B2 (ja) ボールカインポリペプチド及び核酸
JP2005502317A (ja) ボールカインポリペプチド及び核酸
WO2004068135A2 (en) Identification and modification of immunodominant epitopes in polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110711

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111102